KD:NYSEKyndryl Holdings, Inc. Analysis
Data as of 2026-05-23 - not real-time
$12.29
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Kyndryl is trading well below its discounted cash‑flow estimate, offering a sizable margin of safety while its price‑to‑earnings multiple sits comfortably beneath the industry average. Fundamentals show flat revenue, thin margins and zero free cash flow, but a modest forward earnings outlook drives a low forward P/E. The balance sheet is heavily leveraged, with debt far exceeding equity, which amplifies financial risk. Technical indicators point to a bearish environment: the 20‑day moving average sits below the 50‑day average, the MACD line is under its signal, and volume is on a downtrend. RSI hovers around the midpoint, suggesting no extreme momentum, while price remains near a key support level and well below the recent resistance zone. Recent earnings missed estimates and a downgrade from a notable research house have added short‑term pressure, though the stock outperformed its sector over the past month. The market sentiment index signals extreme greed, indicating that broader investor optimism may be overstated for this security. Overall, the stock presents a classic value play with upside potential if the company can improve cash generation and manage its debt load.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- Bearish technical pattern with declining volume
- Recent earnings miss and analyst downgrade
- High leverage increasing financial vulnerability
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Valuation gap to fair value remains sizable
- Forward earnings guidance suggests improving profitability
- Sector dynamics may stabilize after short‑term turbulence
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Significant upside potential relative to discounted cash‑flow estimate
- Low forward P/E indicating cheap growth prospects
- Strategic positioning in high‑growth cloud and AI services
Key Metrics & Analysis
Financial Health
Revenue Growth-0.80%
Profit Margin1.31%
P/E Ratio14.5
ROE14.99%
Debt/Equity303.67
P/B Ratio2.3
Op. Cash Flow$948.0M
Industry P/E39.5
Technical Analysis
TrendBearish
RSI46.0
Support$10.88
Resistance$14.77
MA 20$12.67
MA 50$12.90
MA 200$22.38
MACDBearish
VolumeDecreasing
Fear & Greed Index91.61
Valuation
Fair Value$26.65
Target Price$14.10
Upside/Downside14.73%
GradeUndervalued
TypeBlend
Risk Assessment
Beta1.18
Volatility57.27%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.